MedTrace Logo

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

NCT04150289 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 248

Last updated 2023-06-15

No results posted yet for this study

Summary

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Conditions

Interventions

DRUG

Farydak

non-interventional study

Sponsors & Collaborators

  • pharmaand GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-04
Primary Completion
2022-03-30
Completion
2022-03-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04150289 on ClinicalTrials.gov